TrivarX reshapes leadership and governance to drive digital health commercialisation

An announcement from TrivarX Limited ( (AU:TRI) ) is now available.

TrivarX has terminated the employment of Chief Medical Officer Dr Archie Defillo, who played a key role in developing its MEB-001 and single-channel ECG algorithms, as the company shifts toward a more commercially focused phase. To drive this transition, directors and ResApp Health co-founders Tony Keating and Chris Ntoumenopoulos will take more active roles in commercialisation, drawing on their experience in scaling digital health firms to acquisition.

The company is also searching for a Chief Scientific Officer to bolster its clinical and regulatory leadership, while reshaping its governance team with the resignation of Company Secretary Stephen Buckley and appointment of Cameron Jones and Nova Taylor as joint company secretaries. Director remuneration has been restructured, with Keating and Ntoumenopoulos moving from equity-based to cash-based packages for expanded strategic and regulatory roles, and Chair David Trimboli receiving equity-based fees, underscoring a stronger focus on execution, governance and shareholder value alignment as TrivarX pursues growth.

The most recent analyst rating on (AU:TRI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on TrivarX Limited stock, see the AU:TRI Stock Forecast page.

More about TrivarX Limited

TrivarX Limited is an ASX-listed digital health company focused on mental health and Stabl-Im technologies leveraging medical algorithms, including single-channel ECG-based solutions. The company operates in the healthcare technology sector, targeting commercialisation of clinically validated, AI-driven diagnostic and monitoring platforms in key global markets.

YTD Price Performance: 26.32%

Average Trading Volume: 1,616,483

Technical Sentiment Signal: Hold

Current Market Cap: A$27.69M

For a thorough assessment of TRI stock, go to TipRanks’ Stock Analysis page.